Verona Pharma (VRP)

 

VRP Share PerformanceMore

52 week high210.00 24/10/16
52 week low120.75 17/02/17
52 week change -16.50 (-9.30%)
4 week volume545,365 28/04/17

Media for (VRP)

Presenter: Jan-Anders Karlsson
28/07/2014

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Verona CEO to present at Jefferies Healthcare Conference

Verona Pharma has confirmed that Jan-Anders Karlsson, PhD, CEO of the Company, is scheduled to present at the Jeffer...

Verona Pharma to Present at Jefferies 2017 Global Healthcare Conference

Verona Pharma to Present at Jefferies 2017 Global Healthcare Conference May 23, 2017, LONDON - Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs, an...

Holding(s) in Company

RNS Number: 9441F Verona Pharma PLC 23 May 2017 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Verona Pharma plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights An acquisitio...

Broker Forecast - Jefferies International issues a broker note on Verona Pharma PLC

Jefferies International today initiates coverage of Verona Pharma PLC (LON:VRP) with a buy investment rating and pric...

Partial Exercise of Over-Allotment Option

RNS Number: 2099F Verona Pharma PLC 16 May 2017 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOUL...

Holding(s) in Company

RNS Number: 5192E Verona Pharma PLC 08 May 2017 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Verona Pharma plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights An acquisition...

Holding(s) in Company

RNS Number: 3710E Verona Pharma PLC 05 May 2017 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Verona Pharma plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights An acquisiti...

Holding(s) in Company

RNS Number: 3498E Verona Pharma PLC 05 May 2017 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Verona Pharma PLC 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights x An acquisiti...

Fundamental DataMore

EPS-0.74
Dividend yield0 %

Equity Research (VRP)

edison investment research
Verona Pharma plc
26/07/2016
Verona’s £44.7m gross raise removes funding uncertainty, allowing the company to focus on the clinical progress of its respiratory asset RPL554, a dual PDE3/PDE4 inhibitor. RPL554 is in development...
hardman & co
Verona Pharma plc
20/06/2016
VRP is developing first-in-class drugs to treat unmet medical needs in respiratory disease. Over the last two years’ VRP has reported positive outcomes from a five stage Phase I/IIa programme which...
hardman & co
Verona Pharma plc
16/03/2016
VRP is developing first-in-class drugs that treat unmet medical needs in respiratory disease. RPL554 is being fast-tracked to commercialisation by focusing on a $3.2bn market segment poorly serviced...

Latest discussion posts More

  • Bit of info Arixbioscience

    http://www.proactiveinvestors.co.uk/companies/news/178004/arix-bioscience-hoping-to-generate-venture-capital-style-returns-from-the-life-sciences-industry-178004.html though ...
    18-May-2017
    mol42
  • Re: Our RNS holding releases

    oops meant to add we await update on website re capital structure mol
    16-May-2017
    mol42
  • Re: Our RNS holding releases

    so now we know - out of 865,200 exercisable The underwriters have elected to purchase an additional 692,385 ADSs at the Global Offering price of $13.50 per ADS, raising ...
    16-May-2017
    mol42

Users' HoldingsMore

Users who hold Verona Pharma also hold..
LLOYDS GRP.20%
BP10%
GULF KEYSTONE10%
RENEURON10%
RANGE RES.10%

Codes & Symbols

ISINGB00BYW2KH80
SymbolsVRP, LSE:VRP, VRP.L, VRP:LN, LON:VRP, XLON:VRP